Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

559
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

501
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
501
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

718
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
718

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity history exacerbates liver macrophage-mediated fibrosis via IGFBP7.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

Mechanism by which a linoleic acid metabolite suppresses cancer cell growth by inhibiting mTOR.

Cell chemical biology·2026
Same author

A Biomarker-Driven Ovary-Endometrium Organ-on-a-Chip Mimicking 3D Multicellular Complexity and Menstrual Cyclicity for Predicting Reproductive Toxicity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Anatomical and CBCT-Based Evaluation of the Mental Foramen in Korean Adults: Clinical Implications for Implant Surgery and Mental Nerve Block.

Diagnostics (Basel, Switzerland)·2025
Same author

The SERCA-PLN-DWORF axis in cardiometabolic disease: mechanisms and therapeutic perspectives.

Cardiovascular diabetology·2025
Same author

Systemic inflammation-induced adipose tissue remodeling drives psoriasis exacerbation in obesity through epigenetic and immunometabolic dysregulation.

Theranostics·2025

Related Experiment Video

Updated: Jan 7, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

71.2K

SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration.

Seung Wan Noh1, Han Sol Ryu1, Yong-Ho Kim2

  • 1Department of Health Science and Technology, Gachon Advanced Institute for Health Science and Technology, Gachon University, Incheon, Korea.

Endocrinology and Metabolism (Seoul, Korea)
|January 2, 2026
PubMed
Summary

Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer significant liver benefits beyond blood sugar control. They improve metabolic dysfunction-associated steatotic liver disease (MASLD) by restoring calcium balance and enhancing cellular metabolism.

Keywords:
Endoplasmic reticulum stressInsulin resistanceIntracellular calcium homeostasisLiver diseasesSarcoplasmic reticulum calcium-transporting ATPasesSodium-glucose transporter 2 inhibitors

More Related Videos

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.6K

Related Experiment Videos

Last Updated: Jan 7, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

71.2K
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.6K

Area of Science:

  • Hepatology and Metabolic Medicine
  • Pharmacology and Therapeutics
  • Cellular Biology

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) involves complex systemic metabolic dysregulation.
  • Intracellular calcium (Ca2+) imbalance and endoplasmic reticulum (ER) stress are key contributors to MASLD pathogenesis.
  • Current therapeutic strategies for MASLD often lack comprehensive metabolic control.

Purpose of the Study:

  • To review the multifaceted mechanisms by which SGLT2 inhibitors ameliorate MASLD.
  • To highlight the role of SGLT2 inhibition in systemic metabolic remodeling, mitochondrial function, and Ca2+ homeostasis.
  • To discuss the clinical implications and future directions for SGLT2 inhibitors in treating liver diseases.

Main Methods:

  • Review of preclinical and clinical studies on SGLT2 inhibitors and MASLD.
  • Analysis of molecular pathways including AMPK-SIRT1-PPARγ coactivator-1α and Ca2+-PIP-AKT signaling.
  • Examination of the interplay between renal energy regulation and hepatic resilience via the Ca2+-PIP-SERCA axis.

Main Results:

  • SGLT2 inhibition promotes energy depletion via glucosuria, activating AMPK-SIRT1-PPARγ coactivator-1α pathways for lipid oxidation and autophagy.
  • Restoration of intracellular Ca2+ homeostasis through SERCA2 activation mitigates ER stress and normalizes Ca2+-PIP-AKT signaling.
  • Clinical studies show SGLT2 inhibitors reduce hepatic fat, aminotransferases, and fibrosis markers in MASLD patients, irrespective of diabetes status.

Conclusions:

  • SGLT2 inhibitors represent a novel therapeutic class for MASLD, unifying glucose, lipid, and Ca2+ regulation.
  • These agents enhance hepatocellular function and insulin responsiveness by restoring ER-mitochondrial crosstalk.
  • Future research should focus on biomarkers for patient stratification and developing next-generation SGLT2 analogs targeting Ca2+-dependent pathways.